{"protocolSection":{"identificationModule":{"nctId":"NCT06225024","orgStudyIdInfo":{"id":"University of Health Sciences"},"organization":{"fullName":"Kayseri City Hospital","class":"OTHER_GOV"},"briefTitle":"Efficacy of Extracorporeal Shock Wave Therapy on Spasticity","officialTitle":"Evaluation of the Efficacy of Extracorporeal Shock Wave Therapy (ESWT) Following Botulinum Toxin Type A Injection on Post-Stroke Ankle Plantar Flexor Spasticity"},"statusModule":{"statusVerifiedDate":"2024-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-03-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-06-15","type":"ACTUAL"},"completionDateStruct":{"date":"2023-06-15","type":"ACTUAL"},"studyFirstSubmitDate":"2024-01-07","studyFirstSubmitQcDate":"2024-01-17","studyFirstPostDateStruct":{"date":"2024-01-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-02-10","lastUpdatePostDateStruct":{"date":"2024-02-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Havva Talay Çalış","investigatorTitle":"Prof","investigatorAffiliation":"Kayseri City Hospital"},"leadSponsor":{"name":"Kayseri City Hospital","class":"OTHER_GOV"},"collaborators":[{"name":"Saglik Bilimleri Universitesi","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Introduction: We aimed to compare the efficacy of Botulinum Toxin Type A(BoNT-A) injection and BoNT-A injection in combination with ESWT for post-stroke lower extremity ankle plantar flexor spasticity.\n\nMaterials and Method: Patients with post-stroke ankle plantar flexor spasticity of 1 or more on the modified Ashworth Scale(MAS) were randomized into two groups.\n\nGroup 1(n:20): BoNT-A was injected into the gastrocnemius muscle and conventional physical therapy exercises were performed.\n\nGroup 2(n:20): ESWT was applied to the gastrocnemius muscle in addition to the treatments in group 1.","detailedDescription":"Group 1 (n:20): BoNT-A was injected into the affected gastrocnemius muscle under ultrasonography guidance at doses recommended by standard guidelines and appropriate for the patient (50 IU to the medial head, 25 IU to the lateral head). In addition, conventional physical therapy exercises (stretching exercises, range of motion (ROM) exercises, neurophysiologic exercises, and gait exercises) were applied to the patients five days a week for four weeks.\n\nGroup 2 (n:20): In addition to the treatments (BoNT-A injection and exercise) in Group 1, one week after the injection, a total of 4 sessions (2 days a week) of ESWT (1000 impulses with an energy density of 0.1 mj/mm2, pressure of 2 bar, and frequency of 4 Hz) were applied to the medial and lateral heads of the gastrocnemius muscle.\n\nThe patients in both groups underwent the following evaluations before treatment, at one month and three months after treatment by a treatment-blinded Physical Medicine and Rehabilitation (PMR) physician.\n\nPatients' age, sex, occupation, hemiplegic sides, and etiology of hemiplegia were recorded. Physical examination was performed, and examination findings were recorded. The presence of post-treatment pain, redness, tenderness, or other adverse findings were questioned.\n\nMAS, Brunnstrom Motor Recovery Stage(BMRS), ankle range of motion(ROM) measurement, clonus score(CS), Barthel Index(BI), Heckmatt measurements with ultrasonography, and visual analog scale(VAS) evaluations were performed on the patients."},"conditionsModule":{"conditions":["Stroke","Spasticity, Muscle"],"keywords":["Botulinum Toxin A","ESWT","Stroke","Spasticity","Modified Ashworth Scale","Heckmatt Scale"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Randomized Controlled","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","maskingDescription":"The patients in both groups underwent the following evaluations before treatment, at one month and three months after treatment by a treatment-blinded Physical Medicine and Rehabilitation (PMR) physician:\n\n1. Modified Ashworth Scale (MAS)\n2. Brunnstrom Motor Recovery Stage (BMRS)\n3. Ankle range of motion (2) measurement\n4. Clonus score (CS)\n5. Barthel Index (BI)\n6. Heckmatt measurements with ultrasonography\n7. Visual analog scale (VAS) pain assessment.","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":40,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"BoNT-A","type":"ACTIVE_COMPARATOR","description":"BoNT-A was injected into the affected gastrocnemius muscle under ultrasonography guidance at doses recommended by standard guidelines and appropriate for the patient (50 IU to the medial head, 25 IU to the lateral head). In addition, conventional physical therapy exercises (stretching exercises, range of motion (ROM) exercises, neurophysiologic exercises, and gait exercises) were applied to the patients five days a week for four weeks.","interventionNames":["Drug: BoNT A"]},{"label":"BoNT-A and ESWT","type":"EXPERIMENTAL","description":"In addition to the treatments (BoNT-A injection and exercise) in Group 1, one week after the injection, a total of 4 sessions (2 days a week) of ESWT (1000 impulses with an energy density of 0.1 mj/mm2, pressure of 2 bar, and frequency of 4 Hz) were applied to the medial and lateral heads of the gastrocnemius muscle.","interventionNames":["Device: ESWT","Drug: BoNT A"]}],"interventions":[{"type":"DEVICE","name":"ESWT","description":"Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects","armGroupLabels":["BoNT-A and ESWT"],"otherNames":["device therapy"]},{"type":"DRUG","name":"BoNT A","description":"BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management","armGroupLabels":["BoNT-A","BoNT-A and ESWT"],"otherNames":["drug therapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Modified Ashworth Scale (MAS)","description":"This scale is used to evaluate the severity of spasticity. MAS is based on a subjective evaluation of the resistance felt during the examination.\n\n0: No tone increase\n\n1. Slight increase in tone characterized by a catch and release or minimal resistance at the end of the range of motion 1+: Slight increase in muscle tone with minimal resistance throughout less than half of the range of motion\n2. Increased muscle tone throughout the entire range of motion, but joints can be easily moved\n3. Considerable increase in tone; passive movement is difficult\n4. Affected parts are rigid in flexion and extension.","timeFrame":"at baseline, at one month and three months after treatment"}],"secondaryOutcomes":[{"measure":"Brunnstrom Motor Recovery Stage (BMRS)","description":"It is a motor function assessment scale to evaluate the motor development of hemiplegic patients. According to Brunnstrom, there are six stages in the recovery process of hemiplegic patients, and the upper extremity, lower extremity, and hands are individually evaluated. A higher BMRS indicates better motor development","timeFrame":"at baseline, at one month and three months after treatment"}],"otherOutcomes":[{"measure":"Ankle ROM measurement","description":"Passive joint ROM of the affected ankle was calculated using a goniometer according to the neutral zero method.","timeFrame":"at baseline, at one month and three months after treatment"},{"measure":"Clonus score (CS)","description":"The clonus felt during the examination is graded from 0 to 3. The study evaluated the clonus score by grading the clonus felt while passively moving the affected ankle from maximum plantar flexion to maximum dorsiflexion.\n\nThe clonus scores were interpreted as 0= None, 1= Non-sustained, 2= Sustained, and 3=Spontaneous/Light touch-induced.","timeFrame":"at baseline, at one month and three months after treatment"},{"measure":"Barthel Index (BI)","description":"BI is a detailed, objective, easy-to-administer, and comprehensible scale that assesses physical independence in activities of daily living and thoroughly evaluates all steps of activities of daily living. It was developed to assess the change in functional status in rehabilitation patients. BI consists of 10 main topics. Feeding, transfers from bed to wheelchair and back, grooming, toileting, bathing, mobility on level surfaces (using a wheelchair if appropriate), climbing up and downstairs, dressing, bowel care, and bladder care are questioned. A score of 0-20 indicates complete dependence; a score of 21-61 indicates severe dependence; a score of 62-90 indicates moderate dependence; a score of 91-99 indicates mild dependence; a score of 100 indicates complete independence.","timeFrame":"at baseline, at one month and three months after treatment"},{"measure":"Heckmatt measurements with ultrasonography","description":"The echo intensity within the affected muscle group is assessed and scored with the help of ultrasonography. Echo intensity in the gastrocnemius muscle was visually evaluated in transverse view using a linear probe (Philips Clearvue 550) with an imaging frequency of 5-12 MHz in sonographic examination according to the Heckmatt scale; grade I was recorded as normal; grade II as increased muscle echo intensity with considerable bone echo; grade III as a significant increase in muscle echo intensity and decreased bone echo; grade IV as very high muscle echo intensity and complete loss of bone echo.","timeFrame":"at baseline, at one month and three months after treatment"},{"measure":"Visual analog scale (VAS) pain assessment.","description":"A 10-centimeter line was drawn for pain, one end indicates no pain, and the other indicates severe pain. The patient was asked to mark his/her current condition on this line. The length of the distance from the end which indicates no pain to the point where the patient marks indicates the patient's pain","timeFrame":"at baseline, at one month and three months after treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Being diagnosed with stroke according to the definition of the World Health Organization in 1989\n* Having a stroke confirmed by computed tomography (CT) and magnetic resonance imaging (MRI)\n* Being aged over 18 years\n* Having a MAS score of 1 and above for gastrocnemius, the plantar flexor muscle of the ankle\n* Having a stable general condition after a stroke\n* Giving consent to participate in the study.\n\nExclusion criteria:\n\n* Having a fixed contracture in the ankle\n* Having no spasticity in the soleus, the plantar flexor muscle of the ankle\n* Previous antispastic surgery performed on the area\n* Change in antispastic drug use in the last six months, if any\n* Injection of BoNT-A, alcohol, phenol, or any other substance into the area in the last six months\n* Active infection or cancer at the application site\n* Having a cardiac pacemaker\n* Having bleeding diathesis\n* Having vascular complaints such as deep vein thrombosis, venous stasis, phlebitis, arterial disease\n* Being pregnant\n* Having neuromuscular junction disease or motor neuron disease\n* Having a known allergy to BoNT-A\n* 12. Active use of aminoglycosides or other antibiotic groups.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"HAVVA TALAY ÇALIŞ","affiliation":"KAYSERİ CITY HOSPITAL","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Health Sciences University, Kayseri Medicine Faculty","city":"Kayseri","state":"Kocasinan","zip":"38080","country":"Turkey","geoPoint":{"lat":38.73222,"lon":35.48528}}]},"referencesModule":{"references":[{"pmid":"33906450","type":"BACKGROUND","citation":"Yoldas Aslan S, Kutlay S, Dusunceli Atman E, Elhan AH, Gok H, Kucukdeveci AA. Does extracorporeal shock wave therapy decrease spasticity of ankle plantar flexor muscles in patients with stroke: A randomized controlled trial. Clin Rehabil. 2021 Oct;35(10):1442-1453. doi: 10.1177/02692155211011320. Epub 2021 Apr 28."},{"pmid":"34682846","type":"BACKGROUND","citation":"Yang E, Lew HL, Ozcakar L, Wu CH. Recent Advances in the Treatment of Spasticity: Extracorporeal Shock Wave Therapy. J Clin Med. 2021 Oct 14;10(20):4723. doi: 10.3390/jcm10204723."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M15267","name":"Shock","relevance":"LOW"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000545476","term":"incobotulinumtoxinA"}],"ancestors":[{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","relevance":"LOW"},{"id":"M250157","name":"abobotulinumtoxinA","relevance":"LOW"},{"id":"M20947","name":"Botulinum Toxins, Type A","relevance":"LOW"},{"id":"M250251","name":"incobotulinumtoxinA","asFound":"Lutetium","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":false}